Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Other Non-Current Liabilities (2020 - 2025)

Rapid Micro Biosystems' Other Non-Current Liabilities history spans 6 years, with the latest figure at $397000.0 for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities rose 33.22% to $397000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $397000.0, a 33.22% increase, with the full-year FY2025 number at $397000.0, up 33.22% from a year prior.
  • Other Non-Current Liabilities hit $397000.0 in Q4 2025 for Rapid Micro Biosystems, up from $358000.0 in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for RPID hit a ceiling of $15.6 million in Q2 2021 and a floor of $221000.0 in Q3 2022.
  • Historically, Other Non-Current Liabilities has averaged $2.0 million across 5 years, with a median of $302000.0 in 2024.
  • Biggest five-year swings in Other Non-Current Liabilities: skyrocketed 345.84% in 2021 and later tumbled 95.53% in 2022.
  • Tracing RPID's Other Non-Current Liabilities over 5 years: stood at $1.2 million in 2021, then tumbled by 81.07% to $229000.0 in 2022, then rose by 14.85% to $263000.0 in 2023, then rose by 13.31% to $298000.0 in 2024, then soared by 33.22% to $397000.0 in 2025.
  • Business Quant data shows Other Non-Current Liabilities for RPID at $397000.0 in Q4 2025, $358000.0 in Q3 2025, and $314000.0 in Q2 2025.